BioStrand has announced its collaboration with PGxAI to develop and commercialize its patented foundation AI model, LENSai.
As part of the partnership, PGxAI will support the commercial rollout of the LENSai Application Programming Interface (API) by expanding product features and market reach. This collaboration addresses problems when analyzing and interpreting large amounts of genetic information. LENSai will be an advanced tool that processes LLMs, research, and patient data, enabling custom treatments to improve patient outcomes.
BioStrand, a subsidiary of ImmunoPrecise Antibodies (IPA), is a Belgium-based biotechnology company specializing in genomic analysis and biotherapeutic discovery. It has developed a novel methodology to identify similarities and variations in genetic data. The company's proprietary HYFT technology enables the detection of unique fingerprints in biological sequences, facilitating advanced genomic research and precision medicine applications. BioStrand's offerings include AI-driven tools for sequence retrieval, drug development, and agricultural biotech.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.